Literature DB >> 18603550

t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia.

Paolo Gorello1, Lucia Brandimarte, Roberta La Starza, Valentina Pierini, Loredana Bury, Roberto Rosati, Massimo F Martelli, Peter Vandenberghe, Iwona Wlodarska, Cristina Mecucci.   

Abstract

In a case of acute myeloid leukemia we report molecular cytogenetic findings of a t(3;11)(q12;p15), characterized as a new NUP98 translocation rearranging with LOC348801 at chromosome 3. NUP98 involvement was detected by fluorescence in situ hybridization. 3'-RACE-PCR showed nucleotide 1718 (exon 13) of NUP98 was fused in-frame with nucleotide 1248 (exon 2) of LOC348801. RT-PCR and cloning experiments detected two in-frame spliced NUP98-LOC348801 transcripts and the reciprocal LOC348801-NUP98. A highly specific double-color double-fusion FISH assay reliably detects NUP98-LOC348801.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18603550     DOI: 10.3324/haematol.12945

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

3.  NUP98 fusion oncoproteins interact with the APC/C(Cdc20) as a pseudosubstrate and prevent mitotic checkpoint complex binding.

Authors:  Valentina Salsi; Sebastian Fantini; Vincenzo Zappavigna
Journal:  Cell Cycle       Date:  2016-04-20       Impact factor: 4.534

Review 4.  Nuclear pore proteins and cancer.

Authors:  Songli Xu; Maureen A Powers
Journal:  Semin Cell Dev Biol       Date:  2009-03-18       Impact factor: 7.727

Review 5.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

6.  Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma.

Authors:  Sunniva Stordal Bjørklund; Anshuman Panda; Surendra Kumar; Michael Seiler; Doug Robinson; Jinesh Gheeya; Ming Yao; Grethe I Grenaker Alnæs; Deborah Toppmeyer; Margit Riis; Bjørn Naume; Anne-Lise Børresen-Dale; Vessela N Kristensen; Shridar Ganesan; Gyan Bhanot
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.